- Ticker
- ACER
- Price
- 0.66
- Stock movement down
- -0.14 (-17.95%)
- Company name
- Acer Therapeutics Inc
- Exchange
- (NASDAQ ,
- Currency
- USD )
- Sector
- Healthcare >Biotechnology
- Market cap
- 13.91M
- Ent value
- 35.06M
- Price/Sales
- 38.63
- Price/Book
- -
- Div yield
- -
- Div growth
- -
- Growth years
- -
- FCF payout
- -
- Trailing P/E
- -
- Forward P/E
- -
- PEG
- -
- EPS growth
- -37.96%
- 1 year return
- -43.14%
- 3 year return
- -38.30%
- 5 year return
- -51.33%
- 10 year return
- -42.51%
Last updated: 2024-04-08
DIVIDENDS
ACER does not pay dividends or no data was received
VALUATION
Valuation Ratios
Loading...
Valuation Ratios data
| Trailing P/E | - |
| Price to OCF | - |
| Price to FCF | - |
| Price to EBITDA | - |
| EV to EBITDA | - |
Valuation (Sales/Book Value)
Loading...
Valuation (Sales/Book Value) data
| Price to Sales | 38.63 |
| Price to Book | - |
| EV to Sales | 97.39 |
FINANCIALS
Per share
Loading...
Per share data
| Current share count | 21.07M |
| EPS (TTM) | -1.32 |
| FCF per share (TTM) | -1.65 |
Income statement
Loading...
Income statement data
| Revenue (TTM) | 360.00K |
| Gross profit (TTM) | 0.00 |
| Operating income (TTM) | -23.77M |
| Net income (TTM) | -21.27M |
| EPS (TTM) | -1.32 |
| EPS (1y forward) | -0.66 |
Margins
Loading...
Margins data
| Gross margin (TTM) | - |
| Operating margin (TTM) | -6603.02% |
| Profit margin (TTM) | -5909.34% |
Balance Sheet
Loading...
Please create a free account or log in to access this chart
Balance Sheet data
| Cash | 6.38M |
| Net receivables | 0.00 |
| Total current assets | 7.30M |
| Goodwill | 7.65M |
| Intangible assets | 0.00 |
| Property, plant and equipment | 0.00 |
| Total assets | 15.32M |
| Accounts payable | 4.69M |
| Short/Current long term debt | 8.25M |
| Total current liabilities | 20.79M |
| Total liabilities | 27.53M |
| Shareholder's equity | -12.21M |
| Net tangible assets | -19.85M |
Cash flow
Loading...
Please create a free account or log in to access this chart
Cash flow data
| Operating cash flow (TTM) | -26.38M |
| Capital expenditures (TTM) | 85.23K |
| Free cash flow (TTM) | -26.47M |
| Dividends paid (TTM) | 0.00 |
Financial returns
Loading...
Please create a free account or log in to access this chart
Financial returns data
| Return on Equity | - |
| Return on Assets | -138.82% |
| Return on Invested Capital | 515.60% |
| Cash Return on Invested Capital | 641.53% |
STOCK INFORMATION
Stock chart
Loading...
Stock price data
| Open | 0.80 |
| Daily high | 0.85 |
| Daily low | 0.67 |
| Daily Volume | 575K |
| All-time high | 414221.04 |
| 1y analyst estimate | 8.50 |
| Beta | 0.65 |
| EPS (TTM) | -1.32 |
| Dividend per share | - |
| Ex-div date | - |
| Next earnings date | 13 May 2024 |
Downside potential
Loading...
Downside potential data
| ACER | S&P500 | |
| Current price drop from All-time high | -100.00% | -4.91% |
| Highest price drop | -100.00% | -56.47% |
| Date of highest drop | 30 Aug 2023 | 9 Mar 2009 |
| Avg drop from high | -98.87% | -11.35% |
| Avg time to new high | 436 days | 13 days |
| Max time to new high | 4756 days | 1805 days |
COMPANY DETAILS
Marketcap
13.91M
Marketcap category
Small-cap
Description
Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.
Employees
41
Website
Investor relations
-
SEC filings
CEO
Christopher Schelling
Country
USA
City
Newton
Stock type
Common stock
CCC status
-
Dividend Frequency
-
EVENTS AND PRESENTATIONS
EventsPresentations
Loading...
UNDERSTAND THE BUSINESS
Loading...
COMPANY NEWS
Seeking AlphaPress releases
No items found
iO Charts is a Seeking Alpha partner